Literature DB >> 30402710

Interleukin 28A.rs12980602 and interleukin 28B.rs8103142 genotypes could be protective against HCV infection among Egyptians.

Zainab A Zakaria1,2, Susanne Knapp3, Mohamed Hashem1,4, Hassan Zaghla5, Mark Thursz3, Imam Waked5, Sayed Abdelwahab6,7,8.   

Abstract

Previous studies showed that interleukin (IL)-28B gene polymorphisms were associated with hepatitis C Virus (HCV) infection and treatment outcomes. We tested whether single-nucleotide polymorphisms (SNPs) in IL-28A and IL-28B are associated with HCV infection among Egyptians with HCV genotype 4 infections. We enrolled 144 chronic HCV patients, 72 spontaneously resolved HCV subjects, and 69 healthy controls. Four SNPs in IL-28A and IL-28B genes (IL-28A.rs12980602, IL-28B.rs12979860, IL-28B.rs8099917, and IL-28B.rs8103142) were genotyped. The most frequent IL-28B haplotype "TCT" was significantly more frequent in HCV-infected subjects than in HCV negative subjects (62.2% vs. 48.6%, respectively; p = 0.005). The frequency of IL-28A.rs12980602 "T" allele was significantly higher than the "C" allele in healthy controls compared to HCV-infected subjects (p < 0.001) with the "TT" genotype significantly higher in healthy controls compared to HCV-infected subjects (p < 0.001) with no association with viral load (p = 0.11) among chronically infected subjects. The results, also, confirmed the previous role of IL-28B SNPs in predicting HCV infection outcome. Importantly, IL-28B.rs8099917 "TT" genotype was significantly associated with low viral load in HCV-infected subjects, while the remaining three SNPs did not. The three IL-28B SNPs were in linkage disequilibrium (D' > 0.68; r2 > 0.43) for all comparisons in HCV patients, while there was no linkage disequilibrium of IL-28A polymorphisms and the three IL-28B SNPs. In conclusion, IL-28A.rs12980602 and IL-28B.rs8103142 TT genotype could be protective against HCV infection. Also, IL-28B.rs12979860, IL-28B.rs8099917, and IL-28B.rs8103142 SNPs predicted the outcome of HCV infection among genotype-4-infected Egyptians. Moreover, IL-28B.rs8099917 SNP affected the viral load in chronic HCV patients.

Entities:  

Keywords:  HCV; IFN-λ; IL-28A; IL-28B; Single-nucleotide polymorphism

Mesh:

Substances:

Year:  2019        PMID: 30402710     DOI: 10.1007/s12026-018-9035-2

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  63 in total

1.  Clinical and virological predictors of sustained response with an interferon-based simeprevir regimen for patients with chronic genotype 1 hepatitis C virus infection.

Authors:  Gianpiero D'Offizi; Calogero Cammà; Chiara Taibi; Michael Schlag; Karin Weber; Maria Palma; Ralph DeMasi; Katrien Janssen; James Witek; Raffaella Lionetti
Journal:  New Microbiol       Date:  2017-01-09       Impact factor: 2.479

2.  Risk factors for hepatitis C virus infection among Egyptian healthcare workers in a national liver diseases referral centre.

Authors:  Sayed Abdelwahab; Eman Rewisha; Mohamed Hashem; Maha Sobhy; Iman Galal; Walaa R Allam; Nabeil Mikhail; Gehan Galal; Mohamed El-Tabbakh; Samer S El-Kamary; Imam Waked; G Thomas Strickland
Journal:  Trans R Soc Trop Med Hyg       Date:  2011-12-22       Impact factor: 2.184

3.  IL-28A and IL-29 mediate antiproliferative and antiviral signals in intestinal epithelial cells and murine CMV infection increases colonic IL-28A expression.

Authors:  Stephan Brand; Florian Beigel; Torsten Olszak; Kathrin Zitzmann; Sören T Eichhorst; Jan-Michel Otte; Joachim Diebold; Helmut Diepolder; Barbara Adler; Christoph J Auernhammer; Burkhard Göke; Julia Dambacher
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2005-07-28       Impact factor: 4.052

4.  A single IL28B genotype SNP rs12979860 determination predicts treatment response in patients with chronic hepatitis C Genotype 1 virus.

Authors:  Philippe Halfon; Marc Bourliere; Denis Ouzan; Yaakov Maor; Christophe Renou; Claire Wartelle; Guillaume Pénaranda; Albert Tran; Danielle Botta; Valérie Oules; Paul Castellani; Isabelle Portal; Laurent Argiro; Alain Dessein
Journal:  Eur J Gastroenterol Hepatol       Date:  2011-10       Impact factor: 2.566

5.  Interleukin 28B.rs12979860 genotype does not affect hepatitis C viral load in Egyptians with genotype 4 chronic infection.

Authors:  Sayed F Abdelwahab; Zainab Zakaria; Walaa R Allam; Shaimaa Hamdy; Mohamed A Mahmoud; Maha Sobhy; Eman Rewisha; Imam Waked
Journal:  Arch Virol       Date:  2015-08-18       Impact factor: 2.574

6.  Novel type I interferon IL-28A suppresses hepatitis C viral RNA replication.

Authors:  Haizhen Zhu; Mike Butera; David R Nelson; Chen Liu
Journal:  Virol J       Date:  2005-09-07       Impact factor: 4.099

7.  IL28B gene polymorphism rs12979860, but not rs8099917, contributes to the occurrence of chronic HCV infection in Uruguayan patients.

Authors:  Natalia Echeverría; Daniela Chiodi; Pablo López; Adriana Sanchez Ciceron; Jenniffer Angulo; Marcelo López-Lastra; Paola Silvera; Adrian Canavesi; Carla Bianchi; Valentina Colistro; Juan Cristina; Nelia Hernandez; Pilar Moreno
Journal:  Virol J       Date:  2018-03-02       Impact factor: 4.099

8.  Host genetic factors affecting spontaneous HBsAg seroclearance in chronic hepatitis B patients.

Authors:  Huei-Ru Cheng; Chun-Jen Liu; Tai-Chung Tseng; Tung-Hung Su; Hwai-I Yang; Chien-Jen Chen; Jia-Horng Kao
Journal:  PLoS One       Date:  2013-01-11       Impact factor: 3.240

9.  The favorable IFNL3 genotype escapes mRNA decay mediated by AU-rich elements and hepatitis C virus-induced microRNAs.

Authors:  Adelle P McFarland; Stacy M Horner; Abigail Jarret; Rochelle C Joslyn; Eckart Bindewald; Bruce A Shapiro; Don A Delker; Curt H Hagedorn; Mary Carrington; Michael Gale; Ram Savan
Journal:  Nat Immunol       Date:  2013-11-17       Impact factor: 25.606

Review 10.  Characterizing hepatitis C virus epidemiology in Egypt: systematic reviews, meta-analyses, and meta-regressions.

Authors:  Silva P Kouyoumjian; Hiam Chemaitelly; Laith J Abu-Raddad
Journal:  Sci Rep       Date:  2018-01-26       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.